Eli Lilly and Company (LLY)
Lillys olomorasib receives U.S. FDAs Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
Lillys olomorasib receives U.S. FDAs Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
There are no comments here yet...